Monash IVF rejects revised non-binding indicative proposal
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Monash IVF Group Limited has rejected a revised non-binding indicative proposal from a consortium to acquire the company at a specified price per share. The Board determined that the proposal undervalues the company and is not in the best interest of shareholders. Factors influencing this decision included the offer price being below comparable market transactions and support for the new CEO's strategy. The Board remains open to discussions for a higher valuation but will only consider proposals that represent compelling value for shareholders.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Monash IVF
- Revised NBIO to acquire MVF
- 1H26 Results Presentation
- MVF delivers 1H26 Underlying NPAT of $10.4m
- 1H26 Appendix 4D and Financial Report
- NBIO withdrawn to acquire Monash IVF
Later from Monash IVF
- Trading update
- FY2026 Results release postponed to 31 August 2026
- MVF FY26 Appendix 4E and Financial Report
- MVF FY26 Results Announcement
- MVF FY26 Investor Presentation
Follow Monash IVF into a list and get an email when it puts out news.
Follow Monash IVF